^
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
FDA - 4 days
EGFR exon 20 insertion
NSCLC
amivantamab-vmjw
Sensitive: A1 - Approval
Businesswire - 4 days
EGFR mutation
NSCLC
toripalimab
Sensitive: C2 – Inclusion Criteria
Signal Transduct Target Ther - 4 days
HER-2 exon 20 YVMA insertion
LUAD
ado-trastuzumab emtansine + mobocertinib
Resistant: D – Preclinical
Cancer Res - 4 days
HER-2 exon 20 YVMA insertion
LUAD
mobocertinib
Resistant: D – Preclinical
Cancer Res - 4 days
HER-2 exon 20G776>VC insertion
LUAD
mobocertinib
Sensitive: D – Preclinical
Cancer Res - 4 days
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
JAMA Oncol - 5 days
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
JCO Precis Oncol - 5 days
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
Int J Clin Oncol - 6 days
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
J Thorac Oncol - 1 week
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
PharmaTimes - 6 days
ALK positive
Lung Non-Small Cell Squamous Cancer
brigatinib
Sensitive: C1 - Off-label
Thorac Cancer - 6 days
EGFR mutation
LUAD
osimertinib
Sensitive: C2 – Inclusion Criteria
Zhongguo Fei Ai Za Zhi - 1 week
PTPRD mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
BMC Med - 1 week
ERBB4 mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Mol Med - 1 week
CDKN2A mutation + TMB-H
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
Sci Rep - 1 week
CDKN2A mutation + PD-L1 overexpression
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
Sci Rep - 1 week
PD-L1 overexpression + FGFR3 amplification
NSCLC
nivolumab
Resistant: C4 – Case Studies
Front Oncol - 1 week
PD-L1 overexpression + FGFR3 amplification
NSCLC
nivolumab + anlotinib
Sensitive: C4 – Case Studies
Front Oncol - 1 week
EGFR mutation
LUAD
anlotinib
Resistant: C4 – Case Studies
Zhongguo Fei Ai Za Zhi - 1 week
EGFR mutation
LUAD
pembrolizumab + anlotinib
Sensitive: C4 – Case Studies
Zhongguo Fei Ai Za Zhi - 1 week
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
ESMO Open - 2 weeks
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
JAMA Netw Open - 2 weeks
EGFR mutation
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
J Thorac Oncol - 1 week
ALK positive
LUAD
lorlatinib
Sensitive: C1 - Off-label
Medicine (Baltimore) - 2 weeks
ROS1 G2032R
NSCLC
crizotinib
Resistant: C3 – Early Trials
Respirol Case Rep - 2 weeks
NUP62 rs9523A>G
NSCLC
EGFR inhibitor
Resistant: C3 – Early Trials
Dovepress - 2 weeks
EGFR C797S
LUAD
brigatinib
Sensitive: C3 – Early Trials
Cancer Med - 1 week
EGFR T790M
LUAD
brigatinib
Sensitive: C3 – Early Trials
Cancer Med - 1 week
EGFR exon 19 deletion
LUAD
brigatinib
Sensitive: C3 – Early Trials
Cancer Med - 1 week
EGFR expression + KRAS G12C
NSCLC
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
ESMO Open - 2 weeks
DVL2 rs2074216G>A
LUAD
EGFR inhibitor
Resistant: C3 – Early Trials
Dovepress - 2 weeks
ARF1 rs11541557G>T
LUAD
EGFR inhibitor
Resistant: C3 – Early Trials
Dovepress - 2 weeks
UHRF1 rs2261988C>A
LUAD
EGFR inhibitor
Resistant: C3 – Early Trials
Dovepress - 2 weeks
GHR-ALK fusion
LUAD
crizotinib
Resistant: C4 – Case Studies
J Int Med Res - 2 weeks
ALK positive
LUAD
alectinib + brigatinib
Resistant: C4 – Case Studies
Medicine (Baltimore) - 2 weeks
EGFR exon 19 deletion + EGFR T790M
Small Cell Lung Cancer
etoposide oral
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 2 weeks
ROS1 G2032R
NSCLC
entrectinib
Sensitive: C4 – Case Studies
Respirol Case Rep - 2 weeks
SSTR5 expression
NSCLC
paclitaxel + octreotide
Sensitive: D – Preclinical
Thorac Cancer - 1 week
SSTR2 expression
NSCLC
paclitaxel + octreotide
Sensitive: D – Preclinical
Thorac Cancer - 1 week
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
Future Oncol - 2 weeks
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
Int J Cancer - 3 weeks
EGFR exon 20 insertion + EGFR T790M
NSCLC
afatinib
Resistant: C3 – Early Trials
Int J Cancer - 3 weeks
PD-L1 overexpression + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab + abemaciclib
Sensitive: C3 – Early Trials
JTO Clinical and Research Reports - 3 weeks
SLC8A1-ALK fusion
LUAD
crizotinib
Resistant: C4 – Case Studies
Dovepress - 3 weeks
RB1 deletion
Mesothelioma
BI 6727
Sensitive: D – Preclinical
Cancer Discov - 3 weeks
RB1 deletion
Mesothelioma
MLN8237
Sensitive: D – Preclinical
Cancer Discov - 3 weeks
NF2 mutation
Mesothelioma
verteporfin
Sensitive: D – Preclinical
Cancer Discov - 3 weeks
LATS1 mutation
Mesothelioma
verteporfin
Sensitive: D – Preclinical
J Biol Chem - 3 weeks
LATS2 mutation
Mesothelioma
verteporfin
Sensitive: D – Preclinical
J Biol Chem - 3 weeks
RASSF7 amplification
Mesothelioma
verteporfin
Sensitive: D – Preclinical
J Biol Chem - 3 weeks
HER-2 exon 20 mutation
NSCLC
HM 78136B
Sensitive: B - Late Trials
J Clin Oncol - 3 weeks
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
DP
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
savolitinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
EGFR mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
topotecan
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
pemetrexed
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
NSCLC
carboplatin + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
LUAD
nintedanib
Sensitive: A1 - Approval
EGFR expression
Lung Non-Small Cell Squamous Cancer
necitumumab
Sensitive: A1 - Approval
ALK positive
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRAF V600E
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
pemetrexed
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive: A1 - Approval
No biomarker
NSCLC
docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib
Sensitive: A1 - Approval
ALK positive
NSCLC
ceritinib
Sensitive: A1 - Approval
No biomarker
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
almonertinib
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib + Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
ALK mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
entrectinib
Sensitive: A1 - Approval
BRAF V600
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
ALK positive
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
tislelizumab
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
sintilimab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
ROS1 fusion
NSCLC
crizotinib
Sensitive: A2 - Guideline
ROS1 rearrangement
NSCLC
ceritinib
Sensitive: A2 - Guideline
ROS1 rearrangement
NSCLC
crizotinib
Sensitive: A2 - Guideline
No biomarker
Malignant Pleural Mesothelioma
carboplatin + pemetrexed
Sensitive: A2 - Guideline
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
crizotinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
alectinib
Sensitive: A2 - Guideline
ROS1 positive
NSCLC
lorlatinib
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
osimertinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
ALK inhibitor
Sensitive: A2 - Guideline